Search results for "Anti-VEGF therapy"

showing 2 items of 2 documents

VEGF-targeted therapy stably modulates the glycolytic phenotype of tumor cells

2014

Abstract Anti-VEGF therapy perturbs tumor metabolism, severely impairing oxygen, glucose, and ATP levels. In this study, we investigated the effects of anti-VEGF therapy in multiple experimental tumor models that differ in their glycolytic phenotypes to gain insights into optimal modulation of the metabolic features of this therapy. Prolonged treatments induced vascular regression and necrosis in tumor xenograft models, with highly glycolytic tumors becoming treatment resistant more rapidly than poorly glycolytic tumors. By PET imaging, prolonged treatments yielded an increase in both hypoxic and proliferative regions of tumors. A selection for highly glycolytic cells was noted and this met…

Vascular Endothelial Growth Factor ACancer ResearchPathologymedicine.medical_specialtyNecrosismedicine.medical_treatmentAngiogenesis InhibitorsMice SCIDBiologySCIDAntibodies Monoclonal HumanizedAntibodiesCell LineTargeted therapyMiceRandom AllocationCell Line TumorNeoplasmsMonoclonalAngiogenesis Inhibitors; Animals; Antibodies Monoclonal Humanized; Bevacizumab; Cell Line Tumor; Female; Glycolysis; Humans; MCF-7 Cells; Mice; Mice Inbred BALB C; Mice SCID; Molecular Targeted Therapy; Neoplasms; Phenotype; Random Allocation; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor AssaysmedicineAnimalsHumansGlycolysisMolecular Targeted Therapycancer-cellAnti-VEGF therapyHumanizedInbred BALB CMED/36 - DIAGNOSTICA PER IMMAGINI E RADIOTERAPIAMice Inbred BALB CTumorpositron emission tomography antiangiogenesis glucose metabolism hypoxiaXenograft Model Antitumor AssaysPhenotypeBlockadeBevacizumabVascular endothelial growth factor APhenotypeOncologyCell cultureMonoclonalMCF-7 CellsCancer researchMED/06 - ONCOLOGIA MEDICAFemalemedicine.symptomGlycolysis
researchProduct

Risk of Death Associated With Intravitreal Anti-Vascular Endothelial Growth Factor Therapy: A Systematic Review and Meta-analysis.

2020

Importance Although intravitreal anti–vascular endothelial growth factor (VEGF) treatment represents the first-line therapy for many retinal diseases, the issue of their systemic safety is debatable. Objectives To assess whether intravitreal anti-VEGF therapy might be associated with increased risk of mortality and which variables are associated with the increase. Data Sources PubMed, MEDLINE, and Embase databases, the Cochrane Library, and ClinicalTrials.gov were systematically searched from inception to May 6, 2019. Study Selection Randomized clinical trials comparing intravitreal anti-VEGF treatment with control groups and with follow-up of at least 6 months were selected. Data Extractio…

Vascular Endothelial Growth Factor Amedicine.medical_specialtyDatabases FactualMEDLINEAngiogenesis InhibitorsCochrane LibraryMacular Edemalaw.inventionRandomized controlled triallawFrequentist inferenceInternal medicineCause of DeathRetinal Vein OcclusionMedicineHumansanti-VEGF therapyrisk of mortality anti-vascular endothelial growth factor mortalityCause of deathOriginal InvestigationRandomized Controlled Trials as TopicDiabetic Retinopathybusiness.industryMortality rateOdds ratioChoroidal NeovascularizationOphthalmologyMeta-analysisIntravitreal InjectionsWet Macular DegenerationbusinessJAMA ophthalmology
researchProduct